ilomastat has been researched along with Reperfusion Injury in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belecz, I; Bencsik, P; Csonka, C; Csont, T; Ferdinandy, P; Görbe, A; Kocsis, GF; Pálóczi, J; Pipis, J; Varga, ZV | 1 |
| Chen, CF; Feng, NH; Lin, HI; Wang, D; Wang, NT; Yeh, DY | 1 |
2 other study(ies) available for ilomastat and Reperfusion Injury
| Article | Year |
|---|---|
Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective.
Topics: Animals; Cardiotonic Agents; Cell Survival; Dose-Response Relationship, Drug; Gelatinases; Heart; Hydroxamic Acids; Indoles; Male; Matrix Metalloproteinase Inhibitors; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Primary Cell Culture; Rats; Reperfusion Injury | 2014 |
Matrix metalloprotease expressions in both reperfusion lung injury and oleic acid lung injury models and the protective effects of ilomastat.
Topics: Animals; Enzyme Inhibitors; Femoral Vein; Hydroxamic Acids; Hydroxyl Radical; Indoles; Leukocyte Count; Lung; Lung Injury; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Oleic Acid; Organ Size; Polymerase Chain Reaction; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Reperfusion; Reperfusion Injury; RNA, Messenger | 2009 |